Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 148 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Breast CT Scanning Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Multi-modality Imaging Assessment of Chemobrain

NCT00708045
View directory record Official record
Conditions
Cancer
Interventions
[18F]fluoro-2-deoxy-D-glucose (FDG)
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 14, 2024 · Synced Sep 2, 2026, 5:48 PM EDT
Recruiting Phase 2 Interventional

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

NCT06224673
View directory record Official record
Conditions
HER2 Low Breast Carcinoma, Triple Negative Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma
Interventions
ARX788, Computed Tomography (CT), Biospecimen Collection, Amiloride
Drug · Procedure
Lead sponsor
Laura Huppert, MD, BA
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 2, 2026, 5:48 PM EDT
Recruiting Phase 2 Interventional

Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer

NCT06260033
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, Metastatic Breast Carcinoma
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, F-18 16 Alpha-Fluoroestradiol, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy
Procedure · Drug · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Duarte, California • Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Sep 2, 2026, 5:48 PM EDT
Terminated Phase 1 Interventional

ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC

NCT06351332
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Female, Triple Negative Breast Cancer, Hormone Receptor Negative Malignant Tumor Breast Triple, HER2-negative Breast Cancer
Interventions
Azenosertib, Carboplatin, Pembrolizumab
Drug
Lead sponsor
Filipa Lynce, MD
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 2, 2026, 5:48 PM EDT
Completed Not applicable Interventional Results available

Computed Tomography Versus Standard 2D Mammography Versus 3D Tomosynthesis

NCT01852032
View directory record Official record
Conditions
Breast Cancer
Interventions
Tomosynthesis Breast Scanning, Breast CT Scanning
Radiation
Lead sponsor
University of California, Davis
Other
Eligibility
35 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2018 · Synced Sep 2, 2026, 5:48 PM EDT
Terminated Phase 2Phase 3 Interventional

Contrast-Enhanced Cone Beam Breast CT for Diagnostic Breast Imaging

NCT03354611
View directory record Official record
Conditions
Breast Cancer
Interventions
Contrast Enhanced Cone Beam Breast CT Scan, Contrast Dye, Iodinated
Radiation · Drug
Lead sponsor
Koning Corporation
Industry
Eligibility
35 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Rochester, New York • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Sep 2, 2026, 5:48 PM EDT
Terminated Phase 1 Interventional

Copper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian and Breast Cancer

NCT02708511
View directory record Official record
Conditions
Ovarian Carcinoma, Breast Carcinoma
Interventions
Computed Tomography, Copper Cu 64-DOTA B-Fab, Laboratory Biomarker Analysis, Pharmacological Study, Positron Emission Tomography
Diagnostic Test · Drug · Other
Lead sponsor
Sanjiv Sam Gambhir
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Sep 2, 2026, 5:48 PM EDT
Suspended Phase 1 Interventional

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

NCT05673200
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Decitabine and Cedazuridine, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
10
States / cities
Phoenix, Arizona • Costa Mesa, California • Orange, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 2, 2026, 5:48 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Fluorine-18 3'-Deoxy-3'-Fluorothymidine (F-18-FLT) in Invasive Breast Cancer

NCT00572728
View directory record Official record
Conditions
Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
CT, 18F-FLT, PET
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
27
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Sep 2, 2026, 5:48 PM EDT
Completed No phase listed Observational

Ultrasound Based Localization of Lumpectomy Bed in Anatomical Coordinate System

NCT00681304
View directory record Official record
Conditions
Resected Breast Cancer, Breast Cancer
Interventions
ultrasound scan
Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 15, 2012 · Synced Sep 2, 2026, 5:48 PM EDT
Recruiting Phase 2 Interventional

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

NCT06179303
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable HER2-Negative Breast Carcinoma, Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
Interventions
Abemaciclib, Anastrozole, Biospecimen Collection, Computed Tomography, Diagnostic Imaging Testing, Exemestane, Fludeoxyglucose F-18, Fluorine F 18 Fluoro Furanyl Norprogesterone, Fulvestrant, Gonadotropin-releasing Hormone Analog, Letrozole, Positron Emission Tomography, Tamoxifen, Therapeutic Estradiol
Drug · Procedure · Other + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
St Louis, Missouri • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 2, 2026, 5:48 PM EDT
Active, not recruiting Phase 2 Interventional

Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

NCT05710328
View directory record Official record
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Invasive Breast Carcinoma
Interventions
Chemotherapy, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography, Surgical Procedure
Drug · Procedure · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
97
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 81 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 2, 2026, 5:48 PM EDT
Terminated Not applicable Interventional Results available

PET/CT Evaluation of Treatment Response in Breast Cancer

NCT01222416
View directory record Official record
Conditions
Breast Cancer
Interventions
Radiopharmaceutical Administration [18F]-FDG, Radiopharmaceutical: [18F]-FLT
Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 2, 2026, 5:48 PM EDT
Recruiting Phase 2 Interventional

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

NCT07078604
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
Interventions
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Chemotherapy, Computed Tomography, Sargramostim, Biospecimen Collection, Positron Emission Tomography (PET), Image Guided Biopsy
Biological · Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 2, 2026, 5:48 PM EDT
Active, not recruiting Phase 1 Interventional

[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer

NCT02608216
View directory record Official record
Conditions
Breast Neoplasm, Metastatic Breast Cancer, Rb+ Breast Cancer
Interventions
[18F]FLT, PET/CT, ribociclib, paclitaxel
Drug · Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Sep 2, 2026, 5:48 PM EDT
Recruiting Phase 2 Interventional

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

NCT03606967
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Carboplatin, Computed Tomography, Durvalumab, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Nab-paclitaxel, Personalized Synthetic Long Peptide Vaccine, Poly ICLC, Sacituzumab Govitecan, Tremelimumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
30
States / cities
Orange, California • Sacramento, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 2, 2026, 5:48 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hospital

NCT07146568
View directory record Official record
Conditions
Lung Cancer, Cancer of the Lung
Interventions
Pink and Pearl Campaign
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
20 Years and older
Enrollment
5,515 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 2, 2026, 5:48 PM EDT
Completed Not applicable Interventional Results available

Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?

NCT02286843
View directory record Official record
Conditions
Breast Cancer Metastases, HER2 Positive Breast
Interventions
89Zr-trastuzumab, PET/CT scan, 89Zr-pertuzumab
Radiation · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Sep 2, 2026, 5:48 PM EDT
Recruiting Not applicable Interventional

Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors

NCT05313191
View directory record Official record
Conditions
CNS Cancer, Head and Neck Cancer, GI Cancer, Gynecologic Cancer, Prostate Cancer, Thoracic Cancer, Breast Cancer
Interventions
Pencil Beam Scanning Proton Therapy
Radiation
Lead sponsor
The New York Proton Center
Other
Eligibility
18 Years and older
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 2, 2026, 5:48 PM EDT
Withdrawn Not applicable Interventional

Preoperative Accelerated Partial Breast Irradiation for Triple Negative Breast Cancer Using Proton Beam Scanning

NCT03340402
View directory record Official record
Conditions
Breast Cancer
Interventions
Accelerated Partial Breast Irradiation, AlignRT
Radiation · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Sep 2, 2026, 5:48 PM EDT
Recruiting Not applicable Interventional

Evaluation of Radiobiological Effects in Skin Toxicities for Breast Cancer Patients With Pencil Beam Scanning Proton Therapy

NCT06006806
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage I
Interventions
Pencil Beam Scanning Proton Therapy
Radiation
Lead sponsor
Covenant Health Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Sep 2, 2026, 5:48 PM EDT
Recruiting Phase 1Phase 2 Interventional

Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer

NCT06026657
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Gemcitabine, Magnetic Resonance Imaging, Naxitamab, Universal Donor Expanded TGF-beta-imprinted NK Cells
Procedure · Drug · Biological
Lead sponsor
Margaret Gatti-Mays
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 2, 2026, 5:48 PM EDT
Terminated No phase listed Observational

Imaging of in Vivo Sigma-2 Receptor Expression With 18F-ISO-1 Positron Emission Tomography in Metastatic Breast Cancer

NCT03057743
View directory record Official record
Conditions
METASTATIC BREAST CANCER
Interventions
Positron emission tomography (PET/CT) imaging, radiotracer [18F]ISO-1
Device
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced Sep 2, 2026, 5:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cone Beam Computed Tomography for Breast Imaging

NCT01107860
View directory record Official record
Conditions
Breast Cancer
Interventions
Computed Tomography
Device
Lead sponsor
Koning Corporation
Industry
Eligibility
35 Years and older · Female only
Enrollment
401 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2013 · Synced Sep 2, 2026, 5:48 PM EDT